Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf

An increasing prevalence of immunodeficiency and autoimmune disorders has led to increasing demand for plasma-derived immunoglobulin therapies and a need for scalable and sustainable treatment solutions. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Jörg Schüttrumpf, MD, PhD, Chief Scientific Innovation Officer of Grifols and Chief Executive Officer at Biotest, a Grifols company. The conversation explores advancing immunoglobulin (or IG) treatment for immune disorders, looking broadly at the field and current innovation that is working towards redefining how these therapies are delivered, accessed, and optimised for a growing and diverse patient population. Dr Schüttrumpf also discusses emerging platforms such as recombinant polyclonal therapeutics, as well as the integration of Real World Evidence (RWE) and artificial intelligence (AI) in shaping the future of immunodeficiency care. You can listen to episode 239 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.